Advertisement

Topics

Pharmacokinetics With Two New Oral Nicotine Replacement Products and Nicorette® Gum

2014-08-27 03:12:36 | BioPortfolio

Summary

Single-dose pharmacokinetics with two new oral nicotine replacement products and Nicorette® gum.

Description

The study is a single-dose, randomized, cross-over study. The investigational products will be given as single doses at separate visits. The product administrations comprise 30 minutes of chewing. Periods without NRT, lasting for at least 36 hours, will separate treatment visits. Before and after the start of product administration at each treatment visit, blood will be sampled for pharmacokinetic analyses, pre-dose, and during 8 hours after start of product administration. Used gums will be collected and analyzed to determine the amount of remaining nicotine. Subjects will also be monitored to capture any adverse events that may occur. Treatment labels will be concealed from subjects and study personnel.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Conditions

Tobacco Dependence

Intervention

Nicotine

Location

McNeil AB Clinical Pharmacology R&D
Lund
Sweden
SE-222 20

Status

Completed

Source

Johnson & Johnson Consumer & Personal Products Worldwide

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:12:36-0400

Clinical Trials [947 Associated Clinical Trials listed on BioPortfolio]

Mechanisms of the Nicotine Metabolism Effect on Tobacco Dependence

The purpose of the study is to learn more about tobacco dependence and nicotine metabolism in African-Americans and whites, by studying to see if how fast a person metabolizes nicotine (ho...

Effects of Naltrexone on Nicotine Reinforcement

Despite preclinical evidence supporting the role of the endogenous opioid system in the reinforcing effects of nicotine, the efficacy of the opioid antagonist naltrexone (NTX) as a tobacco...

Manipulating Tobacco Constituents in Male Menthol Smokers

This study examines the potential effect of reducing nicotine content or menthol or both in men. It will also examine whether there are gender differences in manipulating tobacco flavors a...

Smoking Cessation With Smokeless Tobacco, Nicotine Tablets and Nicotine Patches

To test if smokeless tobacco is more effective than nicotine buccal tablets in smoking cessation compared with a control group with low dose nicotine patches. Also retreatment will be tes...

Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms

The proposed work will advance the understanding and effectiveness of tobacco dependence treatment and result in more smokers quitting successfully.

PubMed Articles [2364 Associated PubMed Articles listed on BioPortfolio]

The Effects of Nicotine and Tobacco use on Brain Reward Function: Interaction with Nicotine Dependence Severity.

This study investigated the effects of nicotine/tobacco on neural activation during performance of a monetary incentivized delay task.

Multimodal Neuroimaging Differences in Nicotine Abstinent vs. Satiated Smokers.

Research on cigarette smokers suggests cognitive and behavioral impairments. However, much remains unclear how the functional neurobiology of smokers is influenced by nicotine state. Therefore, we sou...

Nicotine Reduction Strategy: State of the science and challenges to tobacco control policy and FDA tobacco product regulation.

Nicotine addiction is the proximate cause of disease and death from cigarette smoking. In 1994, we proposed reducing the nicotine content of cigarettes to non-addicting levels to reduce the risk of yo...

Electronic cigarettes for adults with tobacco dependence enrolled in a tobacco treatment program: A pilot study.

Electronic cigarettes (ECs) have emerged as a potential harm-reducing alternative for tobacco smokers. However, the role ECs might play in treatment settings is unclear. We conducted an exploratory st...

A retrospective analysis of the association between providing nicotine replacement therapy at admission and motivation to quit and nicotine withdrawal symptoms during an inpatient psychiatric hospitalization.

Psychiatric patients have high tobacco use prevalence, dependence, and withdrawal severity. A tobacco-free psychiatric hospitalization necessitates the management of nicotine withdrawal (NW) for tobac...

Medical and Biotech [MESH] Definitions

Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke.

Tobacco used to the detriment of a person's health or social functioning. Tobacco dependence is included.

A plant genus of the family SOLANACEAE. Members contain NICOTINE and other biologically active chemicals; its dried leaves are used for SMOKING.

The N-glucuronide conjugate of cotinine is a major urinary metabolite of NICOTINE. It thus serves as a biomarker of exposure to tobacco SMOKING. It has CNS stimulating properties.

The aggregate business enterprise of agriculture, manufacture, and distribution related to tobacco and tobacco-derived products.

More From BioPortfolio on "Pharmacokinetics With Two New Oral Nicotine Replacement Products and Nicorette® Gum"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Searches Linking to this Trial